[ Investors » Press Releases ]
2008 | 2007 | 2006 | 2005 | 2004
Press Releases
|
Data on PolyMedix’s Heptagonist Compounds to be Presented at Annual Meeting of the American Society of Hematology Meeting in Atlanta, Georgia, December 9, 2007 |
|
December 6, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in Atlanta, Georgia.
Read More |
|
PolyMedix Appoints Vice President of Drug Development - Bozena Korczak, PhD, Brings Over Twenty Years of Experience to Management Team |
|
November 15, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has appointed Bozena Korczak, PhD, as Vice President of Drug Development.
Read More |
|
PolyMedix’s CEO to Present at Rodman & Renshaw’s Ninth Annual Healthcare Conference on November 6, 2007 |
|
November 4, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will present at Rodman & Renshaw’s Ninth Annual Healthcare Conference taking place November 5 - 7, 2007, at the New York Palace Hotel. Nicholas Landekic, President & C.E.O. of PolyMedix, will give the Company presentation on Tuesday, November 6 at 2:40 PM (EST) in the Spellman Room. Additional information regarding the conference can be found at http://www.rodmanandrenshaw.com/conferences?id=6.
Mr. Landekic will give a brief corporate overview and an update on the Company's recent developments.
Read More |
|
PolyMedix Receives $100,000 Phase I SBIR Grant |
|
Oct 4, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received a Phase I SBIR grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). The SBIR grant, in the amount of $100,000, will be used to support the development of biomimetic compounds as anticoagulant antagonists.
Read More |
|
PolyMedix, Inc. Announces Filing of Registration Statement in Connection with a Common Stock and Warrant Offering of Up to $35 Million |
|
May 9, 2007
PolyMedix, Inc. (OTC BB: PYMX) announced today that it filed a registration statement with the Securities and Exchange Commission relating to a proposed offering of up to $35 million of its common stock and warrants to purchase shares of its common stock to a limited number of institutional investors. Needham & Company, LLC has agreed to act as lead placement agent and WBB Securities, LLC has agreed to act as co-placement agent in connection with the offering.
Read More |
|
PolyMedix Receives Issuance of Patent for Antimicrobial Compounds |
|
February 13, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received issuance of U.S. Patent 7,173,102: Facially Amphiphilic Polymers as Anti-Infective Agents.
Read More |
|
I. Wistar Morris III Resigns from PolyMedix Board. |
|
January 22, 2007
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that I. Wistar Morris III has resigned from the Board of Directors.
Read More |
|
PolyMedix to Present at J.P. Morgan
25th Annual Healthcare Conference
|
|
January 11, 2007
Presentation Scheduled for Thursday January 11 at 2:00 p.m.
PolyMedix, Inc. (OTC BB: PYMX), an emerging
biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that Nicholas Landekic, President and Chief Executive Officer, will present an overview and update on the company at the J.P. Morgan Annual Healthcare Conference being held in San Francisco, January 8-11, 2007. PolyMedix’s presentation is scheduled for Thursday January 11, 2007, at 2:00 p.m. PST at the Westin St. Francis Hotel.
Read More |
Press releases contain forward-looking statements that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," “hopes,” "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forwardlooking
statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
return to top ^ |
